Strategy Notes
Strong sector and geography fit for AI-driven drug resistance prediction with EU focus and funding range alignment. However, the venture is currently pre-seed and unincorporated; EIC Accelerator targets incorporated entities at seed/series-A readiness. Listed as a justified future target—incorporation and proof-of-concept advancement to seed stage are prerequisites.